Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial - Virginie Westeel, Guillaume Eberst, Amelie Anota, Arnaud Scherpereel, Julien Mazieres, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Olivier Molinier, Lena Herve, Frederic Riviere, Isabelle Monnet, Valerie Gounant, Henri Janicot - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

American Society of Clinical Oncology, Journal of Clinical Oncology, 15_suppl(36), p. 8505-8505, 2018

DOI: 10.1200/jco.2018.36.15_suppl.8505

Links

Tools

Export citation

Search in Google Scholar

Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial

Journal article published in 2018 by Virginie Westeel, Guillaume Eberst, Amelie Anota, Arnaud Scherpereel, Julien Mazieres, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Olivier Molinier, Lena Herve, Frederic Riviere, Isabelle Monnet, Valerie Gounant, Henri Janicot and other authors.

This paper is made freely available by the publisher.

This paper is made freely available by the publisher.

Full text: Download

Red circle

Preprint: archiving forbidden

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO